Advertisement
JNJ vs LLY
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Eli Lilly and Company (LLY) Stock Comparison
Key Takeaways
- JNJ offers diversified exposure across pharmaceuticals and medical technology, providing relative stability amid recent market volatility.
- LLY demonstrates stronger revenue growth driven by its incretin portfolio, though the stock has experienced sharper pullbacks in recent weeks.
- Over the past month, JNJ has shown more resilient price behavior compared to LLY, which declined approximately 8% amid broader sector rotation.
- JNJ trades at a lower forward price-to-earnings multiple than LLY, reflecting differences in growth expectations and risk profiles.
- Both companies operate in the healthcare sector with substantial market capitalizations exceeding $600 billion, appealing to investors seeking defensive growth characteristics.
- Recent developments highlight JNJ's pipeline progress in oncology and LLY's investments in artificial intelligence for drug discovery.
Introduction
Johnson & Johnson (JNJ) and Eli Lilly and Company (LLY) represent two prominent healthcare equities frequently examined by investors for their distinct approaches to pharmaceutical innovation and market positioning. This comparison examines their recent performance, business models, and relative characteristics within the current market environment. The analysis is particularly relevant for portfolio managers, institutional investors, and traders evaluating sector allocation between stable dividend payers and high-growth biopharmaceutical names.
JNJ Overview and Recent Performance
Johnson & Johnson operates as a diversified healthcare company with segments in innovative medicine and medical technology. In recent weeks, the stock has traded in a range near $265, reflecting modest declines from earlier highs above $278 amid broader market activity. Positive clinical updates, including data on RYBREVANT for lung cancer and new contact lens approvals, have supported sentiment. The company's established dividend and lower volatility profile have contributed to steadier price behavior compared to more growth-oriented peers during periods of sector rotation.
LLY Overview and Recent Performance
Eli Lilly and Company focuses primarily on pharmaceuticals, with significant contributions from its cardiometabolic and obesity treatments. The stock has pulled back in recent market activity, declining around 8% over the past month from peaks near $1,292, trading near $1,116. Strong year-over-year revenue expansion driven by key products has sustained long-term investor interest, though short-term momentum has moderated amid valuation considerations and profit-taking. Pipeline advancements and strategic investments continue to influence positioning.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots drawn from hundreds of strategies that analyze thousands of tickers. Only the strongest performers suited to prevailing market conditions earn placement in this section, with examples including bots achieving annualized returns in ranges such as 63% to 279% alongside win rates often between 55% and 67%. These robots employ varied styles, timeframes, and risk parameters across diverse ticker sets. Traders can explore the full suite of options and real-time signals on the platform for additional insights.
Head-to-Head Comparison
Johnson & Johnson maintains a broader business model encompassing both pharmaceuticals and medical devices, offering greater diversification and typically lower beta relative to pure-play biopharma names. Eli Lilly concentrates on high-growth therapeutic areas, delivering faster revenue expansion but exposing investors to higher concentration risk around key products. In recent momentum, JNJ has exhibited more consistent trading ranges, while LLY has shown larger swings tied to sector sentiment. Risk factors for JNJ include regulatory pressures on legacy products, whereas LLY faces patent and competition dynamics in its growth categories. Market sentiment favors both for defensive qualities, though LLY commands premium valuations reflecting growth expectations.
Tickeron AI Verdict
Based on observable factors such as trend consistency and relative stability in recent market conditions, Tickeron’s AI models would currently assign a higher probabilistic preference to JNJ for its more resilient price behavior and diversified exposure. Eli Lilly’s stronger growth catalysts remain notable, yet the recent pullback introduces greater short-term variability that may favor defensive positioning in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Buy and LLY is a Buy.
JNJ | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 4 | 10 | |
SMR RATING 1..100 | 37 | 14 | |
PRICE GROWTH RATING 1..100 | 46 | 41 | |
P/E GROWTH RATING 1..100 | 10 | 58 | |
SEASONALITY SCORE 1..100 | 50 | 43 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (51). This means that JNJ’s stock grew somewhat faster than LLY’s over the last 12 months.
JNJ's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is in the same range as LLY (10). This means that JNJ’s stock grew similarly to LLY’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as JNJ (37). This means that LLY’s stock grew similarly to JNJ’s over the last 12 months.
LLY's Price Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as JNJ (46). This means that LLY’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's P/E Growth Rating (10) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (58). This means that JNJ’s stock grew somewhat faster than LLY’s over the last 12 months.
| JNJ | LLY | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 44% | 1 day ago 55% |
| Momentum ODDS (%) | 1 day ago 43% | 1 day ago 63% |
| MACD ODDS (%) | 1 day ago 38% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 39% | 1 day ago 70% |
| TrendMonth ODDS (%) | 1 day ago 51% | 1 day ago 69% |
| Advances ODDS (%) | 2 days ago 47% | 2 days ago 70% |
| Declines ODDS (%) | 7 days ago 40% | 19 days ago 54% |
| BollingerBands ODDS (%) | 1 day ago 39% | N/A |
| Aroon ODDS (%) | 1 day ago 47% | 1 day ago 65% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green while LLY’s FA Score has 2 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- LLY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 3 TA indicator(s) are bullish while LLY’s TA Score has 5 bullish TA indicator(s).
- JNJ’s TA Score: 3 bullish, 4 bearish.
- LLY’s TA Score: 5 bullish, 4 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а -0.60% price change this week, while LLY (@Pharmaceuticals: Major) price change was +1.24% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.68%. For the same industry, the average monthly price growth was -4.26%, and the average quarterly price growth was +11.25%.
Reported Earning Dates
JNJ is expected to report earnings on Oct 13, 2026.
LLY is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.68% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.